Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis.
Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis. Ren Fail. 2020 Nov;42(1):107-112 Authors: Wang Z, Gong Y, Fan F, Yang F, Qiu L, Hong T, Huo Y Abstract Objectives: To evaluate the optimal revascularization strategy for patients with coronary artery disease (CAD) and end stage renal disease (ESRD) in the drug-eluting stent (DES) era.Methods: One hundred and twelve patients with ESRD treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) were enrolled from 2007 to 2017. All patients were dialysis-dependent, of which 26 received CABG and 86 underwent PCI. The primary endpoint was all-cause mortality. Secondary endpoints were major adverse cardiovascular events including myocardial infarction, stroke, repeat revascularization, and death.Results: The CABG group had a higher prevalence of left main CAD (57.7% vs. 11.6%, p
Condition: Hemodialysis Intervention: Sponsor: Washington University School of Medicine Recruiting
Condition: Epilepsy Intractable Intervention: Other: Direct electrical stimulation Sponsors: University of Pennsylvania; National Institute of Neurological Disorders and Stroke (NINDS); Columbia University; Dartmouth College; Emory University; University of Freiburg; Thomas Jefferson University; University of Texas Southwestern Medical Center; Natio nal Institute on Aging (NIA) Recruiting
Conditions: Stroke; Brain Disease; Central Nervous System Diseases; Nervous System Diseases; Cardiovascular Diseases Intervention: Device: Transcranial Magnetic Stimulation Sponsors: VA Pittsburgh Healthcare System; University of Pittsburgh Recruiting
Condition: End Stage Renal Disease on Dialysis Intervention: Sponsors: University of Ioannina; Baxter Healthcare Corporation Recruiting
Conditions: Hyperhomocysteinemia, Thrombotic, Cbs-Related; Ischemic Stroke; Epilepsy Intervention: Genetic: Methylenetetrahydrofolate reductase (MTHFR) deficiency Sponsor: Istanbul Medeniyet University Completed
Authors: Sun HJ Abstract Arterial hypertension remains to be a serious problem with considerable morbidity and mortality worldwide in the present age. Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial infarction, renal failure, and heart failure. Hypertensive nephropathy is the second leading cause of death in chronic kidney disease (CKD) around the world. Long-time hypertension loading results in renal interstitial fibrosis, which is associated with aberrant activation of renal fibroblasts and excessive generation of extracellular matrix (ECM) proteins. Increasing evidence ...
Few studies have investigated the risk of physiological sequelae in living kidney donors (KDs). We conducted a population-based cohort study using the National Health Insurance Research Database of Taiwan, which covers more than 99% of citizens. We comprehensively investigated the risk of medical disorders after kidney donation in living KDs using a maximum follow-up of 13 years. From January 1997 to December 2010, 1081 living KDs and 1082 age- and sex-matched non-KDs were eligible. Primary outcomes comprised end-stage renal disease, chronic kidney disease, stroke, cancer, acute myocardial infarction, acute renal failure ...
Chronic kidney disease (CKD) affects a substantial minority of people with type 2 diabetes (T2D). Analysis of US National Health and Nutrition Examination Survey (NHANES) datasets from 2007 through 2012 showed Stage 3 or worse disease (estimated glomerular filtration rate [eGFR]
Abstract Interest in identifying the most appropriate targets for systolic blood pressure (SBP) lowering to reduce cardiovascular events in persons with hypertension has been piqued by the widely publicized results of the Systolic Blood Pressure Intervention Trial (SPRINT)(1,2). SPRINT found overwhelming benefit (25% reduction in the primary composite outcome of myocardial infarction (MI), acute coronary syndrome not resulting in MI, stroke, acute decompensated heart failure, or death from cardiovascular causes) and 27% reduction in all-cause mortality among participants randomized to a SBP target of